Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel and Carboplatin in Hormone-Refractory Prostate Cancer
NCT00049257Phase 2Completed
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Oct 2002
- Primary completion
- Mar 2009
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel and carboplatin in prostate cancer (PCa), sponsored by UCLA Jonsson Comprehensive Cancer Center. Primary endpoints: Prostate-specific Antigen Response Rate and Time to Prostate-specific Antigen Progression. Started Oct 2002; status: completed.
02
Drugs
paclitaxelcarboplatin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00049257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00049257.